Quick Answer
iBio, Inc. reported Operating Income Loss of -$18.60 million for the year ending 2025.
- iBio, Inc. showed a decrease of -11.8% in Operating Income Loss from 2024 to 2025.
- This data is from iBio, Inc.'s annual report (Form 10-K), filed with the SEC on September 5, 2025.
- XBRL data for this metric is available from 2012 to 2025 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 14 years of available data (2012 to 2025), iBio, Inc.'s Operating Income Loss has declined by 99.4%.
- Historical annual values: Fiscal year 2025: -$18.60 million | Fiscal year 2024: -$16.63 million | Fiscal year 2023: -$29.34 million | Fiscal year 2022: -$29.70 million | Fiscal year 2021: -$31.11 million | Fiscal year 2020: -$14.00 million | Fiscal year 2019: -$15.79 million | Fiscal year 2018: -$14.23 million | Fiscal year 2017: -$14.27 million | Fiscal year 2016: -$9.89 million | Fiscal year 2015: -$6.67 million | Fiscal year 2014: -$3.84 million | Fiscal year 2013: -$6.67 million | Fiscal year 2012: -$9.33 million.
- Data sourced from SEC EDGAR public filings as of June 21, 2026.
Last verified: